Elias Sayour
University of Florida
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elias Sayour as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:59 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07597070 · Universal Immunization to Fortify Immunotherapy Efficacy and ResponseUniversity of Florida · recruiting · Stage 4 NSCLC · principal investigator
- Ph1NCT07492316 · RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)University of Florida · active not recruiting · Recurrent Medulloblastoma · principal investigator
- Ph1NCT04573140 · A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)University of Florida · recruiting · Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma · study chair
- Ph1NCT03396575 · Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)University of Florida · terminated · Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma · principal investigator
- Ph1NCT03334305 · Adoptive Cellular Therapy in Pediatric Patients With High-grade GliomasUniversity of Florida · terminated · Malignant Glioma, High Grade Glioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020R01FD007268 · FDA · UNIVERSITY OF FLORIDA · fiscal years 2022 to 2026 · $1,245,669 awarded in 2026Same name and institution; not confirmed by an ID
- Overcoming the blood-brain barrier with nanoparticle vaccines against gliomasR37CA251978 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2021 to 2026 · $767,498 awarded in 2026Same name and institution; not confirmed by an ID
- RNA Loaded Nanoparticle Aggregates for GlioblastomaR01CA314365 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2026 · $502,391 awarded in 2026Same name and institution; not confirmed by an ID
- Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticlesR01CA266857 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2022 to 2025 · $1,200,245 awarded in 2025Same name and institution; not confirmed by an ID
- Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting GlioblastomaK08CA199224 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2016 to 2020 · $158,188 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade GliomasR01CA195563 · NCI · UNIVERSITY OF FLORIDA · PI DUANE A. MITCHELL, Roger Packer · fiscal years 2015 to 2019Named on NCT03334305
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in medulloblastoma.